CSIMarket Company Name, Ticker, Customers, else..
 
Outlook Therapeutics Inc   (NASDAQ: OTLK)
 
Price: $0.6730 $0.03 5.486%
Day's High: $0.6819999814033508 Week Perf: 4.5 %
Day's Low: $ 0.63 30 Day Perf: -10.98 %
Volume (M): 4,487,017 52 Wk High: $ 2.54
Volume (M$): $ 0 52 Wk Avg: $0.92
Open: $0.64 52 Wk Low: $0.16



 Market Capitalization (Millions $) 92
 Shares Outstanding (Millions) 137
 Employees 17
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -61
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Outlook Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative ophthalmic products. The company is specifically dedicated to creating therapies for diseases and conditions that affect the retina and optic nerve. Outlook Therapeutics works on advanced biologic products that can improve the lives of patients with vision disorders. They prioritize developing solutions that are safe, effective, and affordable.


   Company Address: 111 S. Wood Avenue, Unit #100 Iselin 8830 NJ
   Company Phone Number: 619-3990   Stock Exchange / Ticker: NASDAQ OTLK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -4.46%    
EXEL   -1.34%    
KOD   -5.93%    
OCGN   -25.3%    
BLCO   -2.82%    
EYPT   -19.74%    
• View Complete Report
   



Management Changes

Leadership Change at Outlook Therapeutics: Navigating Challenges Amidst Regulatory Milestones

Published Fri, Jan 31 2025 1:05 PM UTC

In a notable shift within its leadership, Outlook Therapeutics Inc. has appointed Faisal G. Sukhtian as Chairman of the Board of Directors as of January 31, 2025. Sukhtian steps into the role formerly held by Randy Thurman, who will continue to support the company as Lead Independent Director. This transition comes at a pivotal time for Outlook Therapeutics, a biopharmaceuti...
Shares

Outlook Therapeutics Moves Forward: Key Clinical Trial Results for ONS-5010 Bring Hope Amidst Share Price Turmoil,

Published Thu, Jan 16 2025 11:00 AM UTC

Navigating the Waters of Innovation: Outlook Therapeutics Completes NORSE EIGHT Clinical Trial Results On January 16, 2025, Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company renowned for making strides in the ophthalmic space, announced significant developments regarding its clinical trial for the treatment of wet age-related macular degeneration (wet A...
Clinical Study

Outlook Therapeutics A Promising Leap in Wet AMD Treatment with NORSE EIGHT Results

Published Wed, Nov 27 2024 11:50 AM UTC

Outlook Therapeutics, Inc. (Nasdaq: OTLK) is making waves in the biopharmaceutical waters with the announcement of preliminary topline results from the NORSE EIGHT clinical trial, aimed at tackling wet age-related macular degeneration (wet AMD). This pivotal trial marks the second phase in a series of critical evaluations for ONS-5010, a groundbreaking ophthalmic formulation...
Clinical Study

Pioneering Progress in Wet AMD Treatment Outlook Therapeutics Completes Enrollment in Landmark NORSE EIGHT Trial

Published Wed, Sep 4 2024 12:35 PM UTC

Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss in older adults, making advancements in its treatment vitally important. Outlook Therapeutics, Inc. has garnered attention recently with the completion of enrollment in their NORSE EIGHT clinical trial, which is set to evaluate their novel formulation of bevacizumab, ONS-5010, specifically desi...
Product Service News

Breakthrough in Wet AMD Treatment Outlook Therapeutics Receives UK MHRA Marketing Authorization for LYTENAVA (bevaciz...

Published Mon, Jul 8 2024 12:35 PM UTC

Outlook Therapeutics, a reputable biopharmaceutical company, has accomplished a significant milestone in the field of retina diseases. Recently, the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for LYTENAVA (bevacizumab gamma), an innovative ophthalmic formulation developed by Outlook Therapeutics. This breakt...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.39
Working Capital Ratio 0.81
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.96 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.08 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -3,595,486
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) 0.26
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Outlook Therapeutics Inc's Segments

  Outlook Therapeutics Inc Outlook

On May 15 2024 the Outlook Therapeutics Inc provided following guidance

Outlook Therapeutics Inc. reported their financial results for the second quarter of fiscal year 2024 and provided a corporate update on May 15, 2024. The company, listed on Nasdaq as OTLK, is a biopharmaceutical company focused on obtaining regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases.

In their announcement, the company mentioned that they will conduct their first quarterly conference call and live audio webcast on May 16, 2024, at 8:30 AM ET. This is in line with their commitment to transparency and communication with shareholders and the public. Investors and stakeholders are encouraged to participate in this event to gain insights in...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.